Kancera AB (publ)
SSE:KAN.ST
Overview | Financials
Company Name | Kancera AB (publ) |
Symbol | KAN.ST |
Currency | SEK |
Price | 4.095 |
Market Cap | 333,766,251 |
Dividend Yield | 0% |
52-week-range | 2.22 - 6.77 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Thomas Olin Ph.D. |
Website | https://www.kancera.com |
An error occurred while fetching data.
About Kancera AB (publ)
Kancera AB (Publ) develops drugs for inflammatory diseases and cancer in Sweden and internationally. The company is developing small molecule drug candidates KAND567, which is in phase IIa clinical trial for inflammatory heart disease following infarction, as well as KAND145, which is in phase I study in healthy subjects to
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD